Antifungal drugs TDM: trends and update

B Kably, M Launay, A Derobertmasure… - Therapeutic Drug …, 2022 - journals.lww.com
Purpose: The increasing burden of invasive fungal infections results in growing challenges
to antifungal (AF) therapeutic drug monitoring (TDM). This review aims to provide an …

Circulating biomarkers instead of genotyping to establish metabolizer phenotypes

R Tremmel, U Hofmann, M Haag… - Annual Review of …, 2024 - annualreviews.org
Pharmacogenomics (PGx) enables personalized treatment for the prediction of drug
response and to avoid adverse drug reactions. Currently, PGx mainly relies on the genetic …

Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation

AT Nies, E Schaeffeler, M Schwab - Pharmacology & Therapeutics, 2022 - Elsevier
Organic cation transporters (OCT), organic anion transporting polypeptides (OATP) and
organic anion transporters (OAT) from the solute carrier (SLC) family play an essential role …

Pharmacokinetics during therapeutic hypothermia in neonates: from pathophysiology to translational knowledge and physiologically-based pharmacokinetic (PBPK) …

K Leys, MS Stroe, P Annaert… - Expert opinion on …, 2023 - Taylor & Francis
Introduction Perinatal asphyxia (PA) still causes significant morbidity and mortality.
Therapeutic hypothermia (TH) is the only effective therapy for neonates with moderate to …

Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism

CK Cho, P Kang, HJ Park, E Ko, CY Mu, YJ Lee… - Archives of Pharmacal …, 2022 - Springer
Piroxicam is a non-steroidal anti-inflammatory drug used to alleviate symptoms of
osteoarthritis and rheumatoid arthritis. CYP2C9 genetic polymorphism significantly …

Pharmacokinetics of the CYP3A4 and CYP2B6 inducer carbamazepine and its drug–drug interaction potential: a physiologically based pharmacokinetic modeling …

LM Fuhr, FZ Marok, N Hanke, D Selzer, T Lehr - Pharmaceutics, 2021 - mdpi.com
The anticonvulsant carbamazepine is frequently used in the long-term therapy of epilepsy
and is a known substrate and inducer of cytochrome P450 (CYP) 3A4 and CYP2B6 …

Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes

CM Lee, P Kang, CK Cho, HJ Park, YJ Lee… - Archives of Pharmacal …, 2022 - Springer
Metoprolol, a selective β1-adrenoreceptor blocking agent used in the treatment of
hypertension, angina, and heart failure, is primarily metabolized by the CYP2D6 enzyme …

Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?

E Peruzzi, R Roncato, E De Mattia… - British Journal of …, 2023 - Wiley Online Library
Adverse drug reactions (ADRs) account for a large proportion of hospitalizations among
adults and are more common in multimorbid patients, worsening clinical outcomes and …

Novel models for the prediction of drug–gene interactions

D Türk, LM Fuhr, FZ Marok, S Rüdesheim… - Expert Opinion on …, 2021 - Taylor & Francis
ABSTRACT Introduction Adverse drug reactions (ADRs) are among the leading causes of
death, and frequently associated with drug–gene interactions (DGIs). In addition to …

Effects of SLCO1B1 Genetic Variant on Metabolite Profile in Participants on Simvastatin Treatment

L Fernandes Silva, R Ravi, J Vangipurapu, A Oravilahti… - Metabolites, 2022 - mdpi.com
Organic-anion-transporting polypeptide 1B1 (OATP1B1), encoded by the solute carrier
organic anion transporter family member 1B1 gene (SLCO1B1), is highly expressed in the …